JP2020182492A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020182492A5 JP2020182492A5 JP2020128427A JP2020128427A JP2020182492A5 JP 2020182492 A5 JP2020182492 A5 JP 2020182492A5 JP 2020128427 A JP2020128427 A JP 2020128427A JP 2020128427 A JP2020128427 A JP 2020128427A JP 2020182492 A5 JP2020182492 A5 JP 2020182492A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- amino acid
- acid sequence
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 32
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 12
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 206010005003 Bladder cancer Diseases 0.000 claims 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims 6
- 210000004962 mammalian cell Anatomy 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 3
- 102000053602 DNA Human genes 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 201000009036 biliary tract cancer Diseases 0.000 claims 3
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 230000005865 ionizing radiation Effects 0.000 claims 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 3
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 206010038038 rectal cancer Diseases 0.000 claims 3
- 201000001275 rectum cancer Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- -1 HCDR1 Chemical compound 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539687P | 2017-08-01 | 2017-08-01 | |
| US62/539,687 | 2017-08-01 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505392A Division JP6743320B1 (ja) | 2017-08-01 | 2018-07-25 | 抗ｃｄ１３７抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020182492A JP2020182492A (ja) | 2020-11-12 |
| JP2020182492A5 true JP2020182492A5 (cg-RX-API-DMAC7.html) | 2021-09-02 |
| JP7257364B2 JP7257364B2 (ja) | 2023-04-13 |
Family
ID=63165504
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505392A Active JP6743320B1 (ja) | 2017-08-01 | 2018-07-25 | 抗ｃｄ１３７抗体 |
| JP2020128427A Active JP7257364B2 (ja) | 2017-08-01 | 2020-07-29 | 抗ｃｄ１３７抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505392A Active JP6743320B1 (ja) | 2017-08-01 | 2018-07-25 | 抗ｃｄ１３７抗体 |
Country Status (25)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020000342A (es) | 2017-07-11 | 2020-08-17 | Compass Therapeutics Llc | Anticuerpos agonistas que se unen a cd137 humano y sus usos. |
| US11512134B2 (en) | 2017-08-01 | 2022-11-29 | Eli Lilly And Company | Anti-CD137 antibodies |
| CN111182919B (zh) * | 2017-08-01 | 2023-07-07 | 伊莱利利公司 | 抗cd137抗体 |
| WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
| US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| MA52076A (fr) * | 2018-03-23 | 2021-01-27 | Lilly Co Eli | Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-1 |
| ES2946343T3 (es) * | 2018-03-23 | 2023-07-17 | Lilly Co Eli | Anticuerpos anti-CD137 para combinación con anticuerpos anti-PD-L1 |
| US11939381B2 (en) * | 2018-07-19 | 2024-03-26 | Eli Lilly And Company | Bispecific antibodies targeting immune checkpoints |
| CA3107019A1 (en) | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of anti-cd137 antibody drug conjugate (adc) in allogeneic cell therapy |
| CN112839960B (zh) | 2018-08-10 | 2024-09-06 | 中外制药株式会社 | 抗cd137抗原结合分子及其应用 |
| EP3958908A1 (en) | 2019-04-24 | 2022-03-02 | Heidelberg Pharma Research GmbH | Amatoxin antibody-drug conjugates and uses thereof |
| BR112021026309A2 (pt) * | 2019-06-26 | 2022-06-07 | Ap Biosciences Inc | Anticorpos para ativação de células t |
| TWI895351B (zh) * | 2020-02-12 | 2025-09-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
| US20240325538A1 (en) | 2020-11-25 | 2024-10-03 | Shanghai Juncell Therapeutics Co., Ltd. | Tumor infiltration lymphocyte culture medium and application thereof |
| CN120769904A (zh) | 2023-02-27 | 2025-10-10 | 上海君赛生物科技有限公司 | 表达膜结合细胞因子的肿瘤浸润淋巴细胞 |
| KR20250104655A (ko) | 2023-12-29 | 2025-07-08 | 쿠팡 주식회사 | 옵션 피커 화면 제공 방법 및 그 장치 |
| KR20250104669A (ko) | 2023-12-29 | 2025-07-08 | 쿠팡 주식회사 | 옵션 선택 가이드 정보 제공 방법 및 그 장치 |
| KR20250132789A (ko) | 2024-02-29 | 2025-09-05 | 쿠팡 주식회사 | 옵션 피커 화면 제공 방법 및 그 장치 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6362325B1 (en) | 1988-11-07 | 2002-03-26 | Advanced Research And Technology Institute, Inc. | Murine 4-1BB gene |
| US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
| US7211259B1 (en) | 1993-05-07 | 2007-05-01 | Immunex Corporation | 4-1BB polypeptides and DNA encoding 4-1BB polypeptides |
| PL188749B1 (pl) | 1996-10-11 | 2005-04-29 | Bristol Myers Squibb Co | Zastosowanie przeciwciała anty-4-1BB i kompozycjaleku |
| EP1434596B1 (en) | 2001-10-09 | 2009-07-08 | Mayo Foundation For Medical Education And Research | Enhancement of immune responses by agonist 4-1bb-antibodies |
| US7288638B2 (en) * | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| WO2010042433A1 (en) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
| DK2614082T3 (en) * | 2010-09-09 | 2018-11-26 | Pfizer | 4-1BB BINDING MOLECULES |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| EP3102604B1 (en) | 2014-02-04 | 2020-01-15 | Pfizer Inc | Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer |
| US20170247455A1 (en) | 2014-08-22 | 2017-08-31 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| CN107921104A (zh) * | 2015-02-22 | 2018-04-17 | 索伦托治疗有限公司 | 结合cd137的抗体疗法 |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| GB201619648D0 (en) * | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
| CN111182919B (zh) | 2017-08-01 | 2023-07-07 | 伊莱利利公司 | 抗cd137抗体 |
-
2018
- 2018-07-25 CN CN201880064332.2A patent/CN111182919B/zh active Active
- 2018-07-25 KR KR1020207002814A patent/KR102344620B1/ko active Active
- 2018-07-25 EA EA202090204A patent/EA202090204A1/ru unknown
- 2018-07-25 CA CA3071383A patent/CA3071383C/en active Active
- 2018-07-25 BR BR112020001441-9A patent/BR112020001441A2/pt unknown
- 2018-07-25 CA CA3146758A patent/CA3146758A1/en active Pending
- 2018-07-25 AU AU2018311804A patent/AU2018311804B2/en active Active
- 2018-07-25 WO PCT/US2018/043632 patent/WO2019027754A1/en not_active Ceased
- 2018-07-25 MA MA049749A patent/MA49749A/fr unknown
- 2018-07-25 IL IL272349A patent/IL272349B2/en unknown
- 2018-07-25 JP JP2020505392A patent/JP6743320B1/ja active Active
- 2018-07-25 PE PE2020000155A patent/PE20200839A1/es unknown
- 2018-07-25 KR KR1020217041897A patent/KR20210158420A/ko not_active Ceased
- 2018-07-25 US US16/497,493 patent/US10906983B2/en active Active
- 2018-07-25 MX MX2020001351A patent/MX2020001351A/es unknown
- 2018-07-25 EP EP18752950.8A patent/EP3661544B1/en active Active
- 2018-07-25 CR CR20200042A patent/CR20200042A/es unknown
- 2018-07-25 UA UAA202000367A patent/UA128388C2/uk unknown
- 2018-07-25 SG SG11202000747VA patent/SG11202000747VA/en unknown
- 2018-07-25 EP EP22159268.6A patent/EP4070811A1/en not_active Withdrawn
- 2018-07-25 JO JOP/2020/0016A patent/JOP20200016B1/ar active
- 2018-07-25 ES ES18752950T patent/ES2912651T3/es active Active
-
2020
- 2020-01-29 CO CONC2020/0001050A patent/CO2020001050A2/es unknown
- 2020-01-29 SA SA520411186A patent/SA520411186B1/ar unknown
- 2020-01-29 CL CL2020000233A patent/CL2020000233A1/es unknown
- 2020-01-30 PH PH12020500225A patent/PH12020500225A1/en unknown
- 2020-01-31 DO DO2020000020A patent/DOP2020000020A/es unknown
- 2020-01-31 EC ECSENADI20207663A patent/ECSP20007663A/es unknown
- 2020-07-29 JP JP2020128427A patent/JP7257364B2/ja active Active
-
2021
- 2021-12-02 AU AU2021277707A patent/AU2021277707A1/en not_active Abandoned
-
2022
- 2022-11-01 US US18/051,761 patent/US12453771B2/en active Active